Ignite Creation Date:
2024-05-06 @ 12:02 AM
Last Modification Date:
2024-10-26 @ 10:43 AM
Study NCT ID:
NCT01473862
Status:
COMPLETED
Last Update Posted:
2016-08-12
First Post:
2011-11-08
Brief Title:
Adolescent Loss The Impact of Loss on Adolescent Oncology Patients
Sponsor:
St Jude Childrens Research Hospital
Organization:
St Jude Childrens Research Hospital
Study Overview
Official Title:
Adolescent Loss The Impact of Loss on Adolescent Oncology Patients
Status:
COMPLETED
Status Verified Date:
2016-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALOSS
Brief Summary:
Teen loss is not uncommon Depression emptiness disbelief hopelessness and guilt are typical responses How teens with cancer cope with the loss of a loved one or a close friend has not been well-studied in the bereavement or oncology literature This study will describe the impact of loss on teen patients who are on treatment or have recently completed treatment for malignancy We will look at baseline personality traits and ask teens to identify losses in their life We will ask questions about coping and meaning-making after loss A parent will be invited to participate -to measure parental awareness of teen loss and determine if parental coping affects teen coping The inventories have been validated by other researchers
Detailed Description:
All participants will asked to complete a bereavement questionnaire quantifying the losses they have experienced All participants will be screened for depressionanxiety as well as life outlook using validated tools Patients who identify that they have experienced the loss of someone significant in their life on the bereavement questionnaire will continue with the study and complete a battery of validated psychological inventories They will be asked to identify their most significant loss in regards to completion of the remainder of the questionnaire In addition those who identify losing a friend to cancer will be invited to participate in a 30-45 minute semi-structured interview in person or via telephone during a second session with the study staff This interview will be audiotaped to allow for transcription and analysis later Parents will complete demographic information the bereavement questionnaire and complete inventories of family coping cohesion regardless of childs responses to bereavement questionnaire
In addition those who identify losing a friend to cancer will be invited to participate in a 30-45 minute semi-structured interview in person or via telephone during a second session with the study staff
Primary Objectives
Estimate the prevalence of loss with particular interest in the extent of peer loss in adolescent oncology patients who have been on therapy 12 months 6 months if progressive or refractory disease or off therapy for 3 years
Describe the impact of loss on adolescent oncology patients by focusing on coping efficacy psychological distress meaning-making and complicated bereavement
Secondary Objective
Describe parental knowledge of losses experienced by an adolescent child who has recently undergone therapy
In addition those who identify losing a friend to cancer will be invited to participate in a 30-45 minute semi-structured interview in person or via telephone during a second session with the study staff
Primary Objectives
Estimate the prevalence of loss with particular interest in the extent of peer loss in adolescent oncology patients who have been on therapy 12 months 6 months if progressive or refractory disease or off therapy for 3 years
Describe the impact of loss on adolescent oncology patients by focusing on coping efficacy psychological distress meaning-making and complicated bereavement
Secondary Objective
Describe parental knowledge of losses experienced by an adolescent child who has recently undergone therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None